Kaliumchlorid Fresenius

Potassium chloride, the active ingredient in Kaliumchlorid Fresenius, is an electrolyte replacement presented as an intravenous solution for parenteral use. It restores extracellular potassium levels and corrects hypokalemia in patients requiring rapid potassium repletion.

GNH USA supplies Kaliumchlorid Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. Our distribution network ensures timely delivery and regulatory compliance across continents.

Kaliumchlorid Fresenius is used to treat conditions associated with low potassium levels.

- Hypokalemia: restores normal serum potassium concentrations and prevents cardiac arrhythmias. - Potassium replacement therapy: provides controlled potassium infusion during postoperative or critical‑care management. - Diuretic‑induced potassium loss: compensates for potassium depletion caused by loop or thiazide diuretics.

Potassium chloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Vein irritation or phlebitis at the infusion site. - Mild nausea or abdominal discomfort. - Transient hyperkalemia if infused too quickly. - Muscle weakness or tingling sensations.

Serious or Rare Side Effects: - Severe hyperkalemia causing cardiac arrhythmia. - Anaphylactic or severe allergic reaction. - Cardiac arrest. - Metabolic acidosis.

When using Kaliumchlorid Fresenius, careful clinical monitoring is essential.

- Patient assessment: verify serum potassium level before initiation. - Infusion rate: administer slowly, typically not exceeding 10‑20 mEq per hour, to avoid rapid shifts. - Cardiac monitoring: observe ECG for arrhythmias during and after infusion. - Concomitant medications: adjust dose if patient receives ACE inhibitors, ARBs, or potassium‑sparing diuretics. - Renal function: reduce or avoid use in severe renal impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potassium chloride can interact with several medicines; awareness helps prevent complications.

Major Interactions (Avoid): - ACE inhibitors, ARBs, or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Sodium polystyrene sulfonate (Kayexalate): can precipitate when mixed with potassium chloride solutions. - Digoxin: increased risk of digoxin toxicity in the presence of hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal potassium excretion, enhancing hyperkalemia risk. - Beta‑blockers: can mask symptoms of hyperkalemia. - Insulin therapy: insulin drives potassium into cells, potentially causing hypokalemia after potassium infusion.